Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

In 55 people with early breast cancer, ctDNA after curative-intent treatment predicted metastatic relapse, with a median lead time of 7.9 months on serial samples.

Science Translational MedicinePubMed 26311728DOI 10.1126/scitranslmed.aab0021